According to the company, Annovis Bio reported 2025 financial results and corporate updates that show progress in the clinical development of the investigational therapy buntanetap for neurodegenerative diseases. The clinical-stage biotech company said the year was a milestone with the start of a pivotal Phase 3 trial evaluating buntanetap in early Alzheimer’s disease. By March 2026, approximately 65 percent of target participants were enrolled at 83 clinical sites in the United States.
According to the company, the study was designed to evaluate buntanetap over an 18-month period, with both symptomatic effects at six months and potential disease-modifying outcomes throughout the study period. The company also reported biomarker findings from previous studies showing reductions in markers associated with neurodegeneration, neuroinflammation and toxic protein accumulation. In February 2026, the Data and Safety Monitoring Board recommended continuing the phase 3 trial without changes after a six-month phase-in safety review.
In Parkinson’s disease, Annovis initiated an open-label study in early 2026 to evaluate the long-term safety and tolerability of buntanetap for up to 36 months. The company also reported that it is working with the US Food and Drug Administration on a potential study in Parkinson’s disease dementia following clinical findings that showed cognitive improvement in certain groups of patients treated with the therapy.
Financially, research and development expenses increased to $25.2 million in 2025 compared to $20.0 million in 2024, reflecting expanded clinical trial activity. General and administrative expenses decreased to $4.5 million from $6.7 million last year. Annovis reported a net loss of $1.40 per share in 2025. Cash and cash equivalents were $19.5 million at the end of the year, and the company said its current reserves are expected to fund operations through the third quarter of 2026.
Annovis is developing treatments that target the production of neurotoxic proteins implicated in conditions such as Alzheimer’s disease and Parkinson’s disease, with buntanetap designed as a once-a-day oral treatment that addresses multiple pathological pathways associated with neurodegeneration.
